Information:
Error:
ID
34599
Description
Evaluation of Dapagliflozin Taken Twice-daily; ODM derived from: https://clinicaltrials.gov/show/NCT01217892
Link
https://clinicaltrials.gov/show/NCT01217892
Keywords
Versions (1)
- 1/19/19 1/19/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 19, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Type 2 Diabetes NCT01217892
Eligibility Type 2 Diabetes NCT01217892
- StudyEvent: Eligibility
Similar models
Eligibility Type 2 Diabetes NCT01217892
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
provision of informed consent prior to any study specific procedures
boolean
ID.2
Item
diagnosis of t2dm
boolean
ID.3
Item
current antihyperglycaemic treatment with metformin immediate release formulation monotherapy >/= 1500 mg/day at a stable dose for at least 10 weeks prior to enrolment. other treatment with oads within the 10 weeks prior to enrolment is not permitted.
boolean
ID.4
Item
hba1c ≥ 6.7% and ≤10.5%, based on central laboratory values from screening visit, and enrolment visit 1.
boolean
ID.5
Item
diagnosis of type 1 diabetes mellitus, known diagnosis of maturity onset diabetes of the young (mody) or secondary causes of diabetes mellitus
boolean
ID.6
Item
history of diabetic ketoacidosis
boolean
ID.7
Item
symptoms of poorly controlled diabetes including, but not limited to, marked polyuria, polydipsia, and/or greater than 10% weight loss during the 3 months prior to enrolment
boolean
ID.8
Item
fpg >270 mg/dl (>15.0 mmol/l)
boolean
ID.9
Item
bmi >45 kg/m2
boolean